About Juvmo (tavapadon)
In September 2026, the U.S. Food and Drug Administration (FDA) approved Juvmo (tavapadon), a once-daily oral medication for the treatment of motor symptoms of Parkinson’s disease. It was studied both as a standalone treatment in early Parkinson’s and as an add-on to levodopa in people with progressing Parkinson’s.
Tavapadon is a dopamine agonist — a class of Parkinson’s drugs that mimics dopamine, the brain chemical that becomes depleted in Parkinson’s. Rather than being converted into dopamine the way levodopa is, agonists mimic the action of dopamine in the brain.
Pros of Juvmo (tavapadon)
In studies of people who were also taking levodopa, tavapadon added about an hour a day of good symptom control — time when Parkinson’s symptoms are well managed and not accompanied by troublesome involuntary movements, called dyskinesia. It also decreased “off” time, when symptoms aren’t well managed, by about an hour.
In two separate studies of people with early Parkinson’s who were not taking other Parkinson’s medications, tavapadon improved motor symptoms and the ability to manage daily activities more than placebo did, measured over about six months.
Tavapadon is taken as a pill, once a day. Some of the older available dopamine agonists require multiple daily doses, while others are once-daily extended-release pills or a skin patch.
Because tavapadon works on a different group of dopamine receptors from the older dopamine agonists, it may have fewer side effects. However, no study has compared tavapadon’s side effects directly to other dopamine agonists and tavapadon studies may have been too short to realize the full extent of potential side effects over time.
Cons and Complications of Brand Name (tavapadon)
The most common side effects of tavapadon reported in studies included nausea, headache and dizziness. Adding tavapadon to levodopa in progressing Parkinson’s brought some additional side effects, including dyskinesia, hallucinations and orthostatic hypotension — a drop in blood pressure upon standing. Impulse control disorders, daytime sleepiness and hallucinations were all less frequent than with older dopamine agonists, though slightly more common in people with progressing Parkinson’s than in those with earlier-stage disease. Most adverse events were characterized as mild to moderate.
The medical information contained in this article is for general information purposes only. The Michael J. Fox Foundation for Parkinson’s Research has a policy of refraining from advocating, endorsing or promoting any drug therapy, course of treatment, or specific company or institution. It is crucial that care and treatment decisions related to Parkinson’s disease and any other medical condition be made in consultation with a physician or other qualified medical professional.